RESEARCH USE ONLY - Not for human or veterinary use. Supplied for lawful in vitro research and qualified laboratory investigation only. QUALITY - Peptide catalogue items are specified at ≥99% purity with batch documentation. Store lyophilised powders as directed before reconstitution. COMPLIANCE - You are responsible for lawful purchase, possession, and use in your jurisdiction, including institutional and safety requirements. SAFE HANDLING - Use trained personnel, appropriate PPE, and aseptic technique. Do not ingest, inject, or use outside a controlled research setting. POLICIES & ORDERS - Shipping, returns, and research-use terms apply to every order. Read our Research Use Policy and footer legal links before buying.

GLP-TZ 30mg lyophilised vial - for research purposes only

Purity

≥99%

Format

Lyophilised

Documentation

CoA on request

Storage

−20°C

Dual Agonist · Metabolic

GLP-TZ — Tirzepatide (Dual Agonist)

GLP-1 / GIP dual receptor agonist · supplied as 30mg lyophilised powder

≥99% Purity

CoA Available

GLP-TZ is a dual incretin receptor agonist that activates both GLP-1 and GIP receptors. The combined pathway drives complementary metabolic effects - insulin potentiation, glucagon modulation, satiety signalling, and adipose-related mechanisms - and is widely used in obesity, type 2 diabetes, and cardiometabolic research.

Size - 30mg

Available as 30mg lyophilised vial only.

£99.99

View Cart →

What is GLP-TZ?

GLP-TZ is a dual incretin agonist acting on glucagon-like peptide-1 (GLP-1R) and glucose-dependent insulinotropic polypeptide (GIPR) receptors. A fatty-acid moiety supports albumin binding and extended half-life suitable for once-weekly–style protocols in research.

GLP-1R activation promotes glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and enhances satiety. GIPR co-activation adds insulin potentiation and adipose-related effects that together differentiate dual agonism from GLP-1 monotherapy in many models.

Product Code

GLP-TZ

Presentation

30mg vial

Receptor Targets

GLP-1R, GIPR

Mechanism

Dual Agonist

Molecular Weight

~4,814 Da

Sequence Length

39 Amino Acids

Research Background

Published Phase 3–style datasets for this class commonly report:

Large HbA1c reductions in type 2 diabetes models at maximal doses.
Body weight reductions on the order of 20% over extended periods in obesity trials.
Improved fasting and postprandial glucose versus GLP-1 monotherapy comparators.
Favourable shifts in triglycerides and non-HDL cholesterol.
Blood pressure and inflammatory marker improvements in some cohorts.

Research Applications

Type 2 diabetes and insulin resistance
Obesity and body composition
Incretin physiology and dual agonist mechanisms
Cardiometabolic risk markers
Comparisons versus GLP-1 monoagonists

Technical Specifications

Appearance

White Lyophilised Powder

Purity

≥99%

Format

Lyophilised (Freeze-Dried)

Reconstitution

Bacteriostatic Water

Storage (Lyophilised)

−20°C, protected from light

Storage (Reconstituted)

2–8°C, use within 28 days

Shelf Life

24 months (lyophilised)

CoA

Available on Request

Frequently Asked Questions

How does GLP-TZ compare to GLP-SM?

Both activate GLP-1 receptors; GLP-TZ additionally activates GIPR. Many trials report greater weight and glycaemic effects with dual agonism than with GLP-1 monoagonism alone.

What is the recommended reconstitution protocol?

For research use, reconstitute with bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly against the vial wall and swirl gently - do not vortex.

Is a Certificate of Analysis provided?

Yes. A CoA documenting batch purity and specifications is available for every batch on request.